Physician profile
Baotram Tran
NPI 1083840094
$4,682.63
in general payments reported to CMS, 2019-2025
15 companies · $963 in 2025
The $963 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,503 · 2020: $1,141 · 2021: $766 · 2022: $71.99 · 2023: $93.73 · 2024: $144 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,807.59 | 2019-2021 | |
| Mentor Worldwide LLC | $713.84 | 2020-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Musculoskeletal Transplant Foundation INC. | $583.21 | 2020-2025 | |
| Integra Lifesciences Corporation | $389.85 | 2019-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Axogen | $323.00 | 2019-2020 | |
| Motiva USA, LLC | $198.23 | 2025 | |
| Polynovo North America LLC | $149.98 | 2025 | Novosorb Btm |
| Kerecis Limited | $145.59 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Sientra, INC. | $122.87 | 2021-2022 | |
| Abbvie INC. | $93.73 | 2023 | Alloderm |
| Ekos Corporation | $75.90 | 2019 | |
| Coopersurgical, INC. | $22.71 | 2020 | |
| Tela Bio, INC. | $21.07 | 2020 | |
| Kci USA, INC. | $17.73 | 2021 | |
| Galderma Laboratories, L.P. | $17.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baotram Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.